Stock PHARMING GROUP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

PHARMING GROUP Share Price Euronext Amsterdam

Equities

NL0000377018

Pharmaceuticals

End-of-day quote Euronext Amsterdam
Other stock markets
- EUR - Intraday chart for PHARMING GROUP
08/05 Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024
08/05 Pharming Group N.V. Provides Revenue Guidance for 2024 CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 267M 288M 24.02B Sales 2025 * 305M 328M 27.38B Capitalization 594M 640M 53.4B
Net income 2024 * -11M -11.85M -989M Net income 2025 * -10M -10.77M -899M EV / Sales 2024 * 1.9 x
Net cash position 2024 * 87.1M 93.8M 7.83B Net cash position 2025 * 122M 131M 10.93B EV / Sales 2025 * 1.55 x
P/E ratio 2024 *
-294 x
P/E ratio 2025 *
40.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.67%
More Fundamentals * Assessed data

Latest news about PHARMING GROUP

Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024
Pharming Group N.V. Provides Revenue Guidance for 2024 CI
Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Pharming Group to Buy Back EUR123 Million of Bonds due 2025 MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds MT
Pharming Group N.V. announced that it expects to receive ?100 million in funding CI
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024 CI
Pharming Group Seeks Acquisitions CI
Transcript : Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Pharming Group N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating MT
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies CI
More news

Latest transcript on PHARMING GROUP

Logo PHARMING GROUP
Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024
More transcripts

Analyst Recommendations on PHARMING GROUP

RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating MT
Oppenheimer Adjusts Pharming Group Price Target to $40 From $36, Maintains Outperform Rating MT
Oppenheimer Adjusts Pharming Group's Price Target to $36 From $43, Maintains Outperform Rating MT
Van Leeuwenhoeck issues research note on Pharming (PHAR.AS): Turning the Page PU
More recommendations

Press releases PHARMING GROUP

Pharming N : 1Q 2024 Financial Results Presentation - May 8, 2024 PU
Pharming Group reports first quarter 2024 financial results and provides business update AQ
Pharming Group reports first quarter 2024 financial results and provides business update GL
Pharming N : Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 - Form 6-K PU
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders 2024 Rare Impact Awards AQ
More press releases

News in other languages on PHARMING GROUP

RBC verlaagt koersdoel Pharming
AEX zakt net onder recordstand
Flinke omzetstijging Pharming
AEX toch hoger van start gegaan
AEX start handelsdag vermoedelijk licht lager
More news

Managers and Directors - PHARMING GROUP

Managers TitleAgeSince
Sijmen de Vries CEO
 Chief Executive Officer 65 13/08/13
Jeroen Wakkerman DFI
 Director of Finance/CFO 55 16/20/16
Anurag Relan CTO
 Chief Tech/Sci/R&D Officer 52 -
Members of the board TitleAgeSince
Mark Pykett BRD
 Director/Board Member 60 11/20/11
Leonard Kruimer BRD
 Director/Board Member 66 19/21/19
Sijmen de Vries CEO
 Chief Executive Officer 65 13/08/13
More insiders

Company Profile

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
Sector
Pharmaceuticals
Calendar
21/05/2024 - Annual General Meeting
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PHARM Stock
  4. Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW